NSE ScannerChemicals · Chemicals: Specialty · NSE: PAR · data 2026-10-30
Par Drugs and Chemicals Limited
In plain words
Price: 36.3% below its 52-week high of ₹180.
Delivery: 54.0% of traded shares were kept for delivery over the last 10 sessions, against 67.4% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Dec 2023.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹108 cr |
| Net profit (last 12 months) | ₹13 cr |
| Sales growth, 3 years (yearly) | 2.7% |
| Profit growth, 3 years (yearly) | 5.0% |
Latest results in brief (Q2 FY27)
PAR Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹27.43 crore, down 4.3% YoY and down 12.3% QoQ.
Net profit was ₹2.63 crore, down 36.3% YoY and down 44.2% QoQ.
Operating margin was 16.4% (21.2% a year ago).
EPS was ₹2.14, down 36.3% YoY and down 44.1% QoQ.
PAR के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹27.43 करोड़; पिछले साल की तुलना में 4.3% की गिरावट, पिछली तिमाही की तुलना में 12.3% की गिरावट।
शुद्ध मुनाफ़ा: ₹2.63 करोड़; पिछले साल की तुलना में 36.3% की गिरावट, पिछली तिमाही की तुलना में 44.2% की गिरावट।
ऑपरेटिंग मार्जिन: 16.4% (एक साल पहले 21.2%)।
EPS: ₹2.14; पिछले साल की तुलना में 36.3% की गिरावट, पिछली तिमाही की तुलना में 44.1% की गिरावट।
PARના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹27.43 કરોડ; ગયા વર્ષની સરખામણીએ 4.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 12.3% ઘટાડો.
ચોખ્ખો નફો: ₹2.63 કરોડ; ગયા વર્ષની સરખામણીએ 36.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 44.2% ઘટાડો.
ઓપરેટિંગ માર્જિન: 16.4% (એક વર્ષ પહેલાં 21.2%).
EPS: ₹2.14; ગયા વર્ષની સરખામણીએ 36.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 44.1% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
22/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 17/20: Net +₹0.83 cr bought in bulk/block deals over 90 days (8.3x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal
- 2 Sept 26Deal Bulk deal: NIKUNJ SHAH bought ₹0.83 cr +17.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2023 | ₹24 cr | ₹3 cr | — | 21.8% | 2.78 |
| Sept 2023 | ₹26 cr | ₹5 cr | — | 28.4% | 3.97 |
| Mar 2023 | ₹24 cr | ₹3 cr | — | 22.0% | 2.8 |
Common questions
What was Par Drugs and Chemicals Limited's latest quarterly profit?
Par Drugs and Chemicals Limited reported a net profit of ₹3 cr for the quarter ended Dec 2023, on revenue of ₹24 cr.
Is Par Drugs and Chemicals Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Par Drugs and Chemicals Limited's P/E ratio?
About 10.9, based on the last 12 months' earnings and a price of ₹114.67 (data 2026-10-30).
What is the 52-week high and low of Par Drugs and Chemicals Limited?
The 52-week high is ₹180 and the 52-week low is ₹78.05.
Similar companies
Signet Industries Limited (SIGIND) · Kanchi Karpooram Ltd (KANCHI) · Ambani Orgochem Ltd (AMBANIORGO) · Rajputana Biodiesel Limited (RAJPUTANA) · Hindprakash Industries Ltd. (HPIL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PAR in NSE Scanner →